** Shares of drug developer Denali Therapeutics fall 6.7% to $18.50 premarket
** Co late on Monday said its experimental ALS drug failed to meet the main goal of a mid-to-late stage study
** Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease
** Co said the drug, DNL343, did not demonstrate a change in disease severity over time and in survival compared to placebo
** The drug also did not meet key secondary goals of statistically significant improvements in muscle strength and respiratory function
** Brokerage H.C. Wainwright cuts PT to $87 from $90, says "the results are not shocking given the complexities of conducting a perfect ALS trial"
** Up to last close, stock had fallen 5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。